Pfizer (NYSE: PFE) reported earnings on May 1. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended April 1 (Q1), Pfizer met expectations on revenues and beat slightly on earnings per share.

Compared to the prior-year quarter, revenue contracted and GAAP earnings per share shrank.

Gross margins contracted, operating margins expanded, and net margins dropped.

Revenue details
Pfizer notched revenue of $15.41 billion. The 14 analysts polled by S&P Capital IQ predicted revenue of $15.43 billion on the same basis. GAAP reported sales were 6.6% lower than the prior-year quarter's $16.50 billion.

My

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $0.58. The 17 earnings estimates compiled by S&P Capital IQ averaged $0.57 per share. GAAP EPS of $0.24 for Q1 were 14% lower than the prior-year quarter's $0.28 per share. (The prior-year quarter included $0.00 per share in earnings from discontinued operations.)

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 81.2%, 10 basis points worse than the prior-year quarter. Operating margin was 33.9%, 40 basis points better than the prior-year quarter. Net margin was 11.6%, 190 basis points worse than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $15.16 billion. On the bottom line, the average EPS estimate is $0.55.

Next year's average estimate for revenue is $61.43 billion. The average EPS estimate is $2.24.

Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 5,502 members out of 6,094 rating the stock outperform, and 592 members rating it underperform. Among 1,442 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 1,345 give Pfizer a green thumbs-up, and 97 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Pfizer is outperform, with an average price target of $24.33.

Can your portfolio provide you with enough income to last through retirement? You'll need more than Pfizer. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.